2024-05-21 08:15:00 ET
Summary
- Hims & Hers Health's share price increased by over 25% after announcing the availability of compounded GLP-1 agonist weight loss drugs at a fraction of the price of branded drugs.
- The company aims to capitalize on the shortages of the branded drugs Wegovy and Zepbound, which are expected to dominate a potential $100 billion industry.
- Hims & Hers' partnership with a manufacturer of generic and compounded medications allows it to offer these drugs without supply shortages, potentially generating significant revenue.
Investment Overview
Read the full article on Seeking Alpha
For further details see:
Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead